Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Syfovre Eye Injections Adverse Reactions Update August 2023

August 23, 2023 By Law Offices of Thomas J. Lamb, P.A.

We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS).

Apellis Pharmaceuticals said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss cases involve a type of eye inflammation called retinal vasculitis. Four Syfovre patients have developed occlusive retinal vasculitis, a possibly blinding condition in which blood flow to the retina is blocked.

The ASRS shared a timeline of events related to these cases of Syfovre eye injections adverse reactions, as outlined below:

  • July 3, 2023: The first report of panuveitis with retinal occlusive vasculitis was received by the ASRS Research and Safety in Therapeutics (ReST) Committee.
  • July 5, 2023: ReST contacted Apellis to discuss safety concerns arising from this first Syfovre vision loss case.
  • July 6-12, 2023: The ASRS received six additional reports of Syfovre eye injections adverse reactions in patients.
  • July 12, 2023: Apellis and the ASRS Research and Safety in Therapeutics (ReST) Committee met to discuss severe intraocular inflammation and cases of vasculitis in patients who had received Syfovre eye injections.
  • July 15, 2023: The ASRS Executive Committee unanimously approved the Syfovre safety concerns “communication”, which was agreed to by Apellis and sent to ASRS members that same day.

It has been reported by medical news sources that as of late July 2023, Apellis Pharmaceuticals does not know the cause, yet, for these seven cases of Syfovre eye injections adverse reactions. Further, Apellis has said that so far the company has only been able to rule out drug product quality and manufacturing issues.

As such, other possible causes for these Syfovre vision loss cases involving retinal vasculitis remain to be researched.

We are investigating Syfovre vision loss cases as drug injury lawsuits against Apellis Pharmaceuticals for patients who developed occlusive retinal vasculitis or eye inflammation after receiving a Syfovre eye injection.

[View article at original source]

Syfovre

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: occlusive retinal vasculitis, retinal vasculitis, Syfovre, vision loss

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.